PT - JOURNAL ARTICLE AU - Carina Dehner AU - Chang In Moon AU - Zhaohe Zhou AU - Xiyuan Zhang AU - Chris Miller AU - Hua Xu AU - Xiaodan Wan AU - Kuangying Yang AU - Jay Mashl AU - Sara J.C. Gosline AU - Yuxi Wang AU - Xiaochun Zhang AU - Abigail Godec AU - Paul A. Jones AU - Sonika Dahiya AU - Himanshi Bhatia AU - Tina Primeau AU - Shunqiang Li AU - Kai Pollard AU - Li Ding AU - Christine A. Pratilas AU - Jack F. Shern AU - Angela C. Hirbe TI - Chromosome 8 gain is associated with high-grade transformation in MPNST AID - 10.1101/2020.12.04.20242818 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.04.20242818 4099 - http://medrxiv.org/content/early/2020/12/07/2020.12.04.20242818.short 4100 - http://medrxiv.org/content/early/2020/12/07/2020.12.04.20242818.full AB - One of the most common malignancies affecting adults with Neurofibromatosis type 1 (NF1) is the malignant peripheral nerve sheath tumor (MPNST), an aggressive and often fatal sarcoma which commonly arises from benign plexiform neurofibromas. Despite advances in our understanding of MPNST pathobiology, there are few effective therapeutic options, and no investigational agents have proven success in clinical trials. To further understand the genomic heterogeneity of MPNST, and to generate a preclinical platform that encompasses this heterogeneity, we developed a collection of NF1-MPNST patient derived xenografts (PDX). These PDX were compared to the primary tumors from which they were derived using copy number analysis, whole exome and RNA sequencing. We identified chromosome 8 gain as a recurrent genomic event in MPNST and validated its occurrence by FISH in the PDX and parental tumors, in a validation cohort, and by single cell sequencing in the PDX. Finally, we show that chromosome 8 gain is associated with inferior overall survival in soft tissue sarcomas. Taken together, these data suggest that chromosome 8 gain is a critical event in MPNST pathogenesis, and may account for the aggressive nature and poor outcomes in this sarcoma subtype.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grants from the Neurofibromatosis Translational Acceleration Program to Angela Hirbe and Christine Pratilas. The Neurofibromatosis Research Initiative to Angela Hirbe and the St. Louis Mens Group Against Cancer to Angela Hirbe.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was performed under protocol number #201203042 which was approved by the Washington University Institutional Review Board and protocol #J1649, which was approved by the Johns Hopkins Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSYNAPSE repository: doi:10.7303/syn11638893 https://www.synapse.org/#!Synapse:syn11638893